{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:24:21Z","timestamp":1781774661773,"version":"3.54.5"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011132","name":"Rutgers, The State University of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infection involves pulmonary inflammation that can progress to acute respiratory distress syndrome, a primary cause of lung damage\/fibrosis in patients with Coronavirus Disease-2019 (COVID-19). Currently, there is no efficacious therapy available to alleviate lung fibrosis in COVID-19 cases. In this proof-of-concept study, we evaluated the effect of CC-11050, a small molecule phosphodiesterase-4 inhibitor, in dampening lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following intranasal inoculation with SARS-CoV-2\/WA- 1\/2000 strain, hamsters were treated with CC-11050 or placebo by gavage from day-1 until day-16 post-infection (dpi). Animals were monitored for body weight changes, virus titers, histopathology, fibrotic remodeling, cellular composition in the lungs between 2 and 16 dpi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed significant reduction in lung viral titer with concomitant reduction in inflammation and fibrotic remodeling in CC-11050 treated hamsters compared to untreated animals. The reductions in immunopathologic manifestations were associated with significant downregulation of inflammatory and fibrotic remodeling gene expression, reduced infiltration of activated monocytes, granulocytes, and reticular fibroblasts in CC-11050 treated animals. Cellular studies indicate a link between TNF-\u03b1 and fibrotic remodeling during CC-11050 therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings suggest that CC-11050 may be a potential host-directed therapy to dampen inflammation and fibrosis in COVID-19 cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1270414","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:02:13Z","timestamp":1696262533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Afsal","family":"Kolloli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhamani","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annuurun","family":"Nisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilla","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvakumar","family":"Subbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"B1","unstructured":"Coronavirus (COVID-19) Dashboard"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00299-20","article-title":"Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"crossref","first-page":"e01041","DOI":"10.1016\/j.idcr.2020.e01041","article-title":"Post COVID-19 fibrosis, an emerging complication of SARS-CoV-2 infection","volume":"23","author":"Ahmad Alhiyari","year":"2021","journal-title":"IDCases"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12079-020-00569-0","article-title":"COVID-19: is fibrosis the killer","volume":"14","author":"Leask","year":"2020","journal-title":"J Cell Commun Signal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.01.015","article-title":"Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model","volume":"4","author":"Subbian","year":"2016","journal-title":"EBioMedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00450","article-title":"Thalidomide and phosphodiesterase 4 inhibitors as host directed therapeutics for Tuberculous meningitis: insights from the rabbit model","volume":"9","author":"Kumar","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e17091","DOI":"10.1371\/journal.pone.0017091","article-title":"Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice","volume":"6","author":"Koo","year":"2011","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1002262","DOI":"10.1371\/journal.ppat.1002262","article-title":"Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs","volume":"7","author":"Subbian","year":"2011","journal-title":"PloS Pathog"},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajpath.2011.03.039","article-title":"Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology","volume":"179","author":"Subbian","year":"2011","journal-title":"Am J Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00238","article-title":"Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis","volume":"7","author":"Subbian","year":"2016","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0121725","DOI":"10.1371\/journal.pone.0121725","article-title":"The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation","volume":"10","author":"Konrad","year":"2015","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/biomedicines10061343","article-title":"Comprehensive analysis of disease pathology in immunocompetent and immunocompromised hosts following pulmonary SARS-CoV-2 infection","volume":"10","author":"Ramasamy","year":"2022","journal-title":"Biomedicines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.092134099","article-title":"Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans","volume":"99","author":"Zuo","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5782","article-title":"Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis","volume":"172","author":"Kimura","year":"2004","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01117","article-title":"Quantification of lung fibrosis in IPF-like mouse model and pharmacological response to treatment by micro-computed tomography","volume":"11","author":"Ruscitti","year":"2020","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1507387112","article-title":"TNF-alpha-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation","volume":"112","author":"Pilling","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.3390\/ijms21114008","article-title":"A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-beta Signaling and Activation of cAMP\/PKA Signaling","volume":"21","author":"Wojcik-Pszczola","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.3390\/nu14235068","article-title":"Eating habits and body weight changes induced by variation in smell and taste in patients with previous SARS-CoV-2 infection","volume":"14","author":"Ferrulli","year":"2022","journal-title":"Nutrients"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jcsm.12674","article-title":"Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers","volume":"12","author":"Anker","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00697-4","article-title":"COVID-19 instigates adipose browning and atrophy through VEGF in small mammals","volume":"4","author":"Jing","year":"2022","journal-title":"Nat Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02069","article-title":"Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider","volume":"11","author":"Garcia-Revilla","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"104351","DOI":"10.1016\/j.ebiom.2022.104351","article-title":"Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation","volume":"86","author":"Jyothula","year":"2022","journal-title":"EBioMedicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"104428","DOI":"10.1016\/j.ebiom.2022.104428","article-title":"Rigid respiration: fulminant pulmonary fibrosis after COVID-19","volume":"87","author":"Meyerholz","year":"2023","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/path.5642","article-title":"COVID-19: immunopathology, pathophysiological mechanisms, and treatment options","volume":"254","author":"van Eijk","year":"2021","journal-title":"J Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1038\/s41467-022-30088-y","article-title":"SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505291200","article-title":"Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2","volume":"280","author":"Theiss","year":"2005","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209229","article-title":"The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome","volume":"72","author":"Dorward","year":"2017","journal-title":"Thorax"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00805-z","article-title":"Patients with COVID-19: in the dark-NETs of neutrophils","volume":"28","author":"Ackermann","year":"2021","journal-title":"Cell Death Differ"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0635-3","article-title":"Lymph node stromal cells: cartographers of the immune system","volume":"21","author":"Krishnamurty","year":"2020","journal-title":"Nat Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149263","article-title":"Collagen type VI is the antigen recognized by the ER-TR7 antibody","volume":"51","author":"Schiavinato","year":"2021","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203153","article-title":"Six-month follow-up chest CT findings after severe COVID-19 pneumonia","volume":"299","author":"Han","year":"2021","journal-title":"Radiology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s43055-021-00484-3","article-title":"Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients","volume":"52","author":"Ali RMM","year":"2021","journal-title":"Egypt J Radiol Nucl Med"},{"key":"B46","first-page":"103590","article-title":"Post COVID-19 pulmonary fibrosis; a meta-analysis study","volume":"77","author":"Hama Amin","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-beta: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.5.1546-1552.2000","article-title":"Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation","volume":"20","author":"Cardinaux","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700186200","article-title":"Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling","volume":"282","author":"Chen","year":"2007","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.038620","article-title":"Increased cAMP levels modulate transforming growth factor-beta\/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions","volume":"285","author":"Schiller","year":"2010","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00171","article-title":"Host-directed therapeutic strategies for tuberculosis","volume":"4","author":"Kolloli","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758837","article-title":"Use of antiviral agents and other therapies for COVID-19","volume":"44","author":"Blaskovich","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"25151355221144845","DOI":"10.1177\/25151355221144845","article-title":"Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus","volume":"10","author":"Oliver","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B55","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1186\/s13063-020-04643-1","article-title":"Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial","volume":"21","author":"Villar","year":"2020","journal-title":"Trials"},{"key":"B58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-020-04646-y","article-title":"High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Maskin","year":"2020","journal-title":"Trials"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00500-z","article-title":"Potential adverse effects of dexamethasone therapy on COVID-19 patients: review and recommendations","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"173854","DOI":"10.1016\/j.ejphar.2021.173854","article-title":"Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic","volume":"894","author":"Noreen","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"109130","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12879-021-05912-3","article-title":"Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India","volume":"21","author":"Gokhale","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0824-3","article-title":"Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial","volume":"15","author":"Wang","year":"2021","journal-title":"Front Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30309-X","article-title":"Accumulating evidence suggests anti- TNF therapy needs to be given trial priority in COVID-19 treatment","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13054-020-03158-0","article-title":"Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series","volume":"24","author":"Stallmach","year":"2020","journal-title":"Crit Care"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1136\/annrheumdis-2020-218171","article-title":"COVID-19 in patients with rheumatological diseases treated with anti-TNF","volume":"80","author":"Brito","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.41596","article-title":"American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3","volume":"73","author":"Mikuls","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.833967","article-title":"Targeting TNF-alpha for COVID-19: recent advanced and controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front Public Health"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13543784.2023.2173061","article-title":"BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)","volume":"32","author":"Sgalla","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1270414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:02:21Z","timestamp":1696262541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1270414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2023.1270414"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1270414","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"article-number":"1270414"}}